One of the most important #globaloncology #cancerpolicy studies our group has published.We talk a lot about "meaningful benefit" or "appropriate prices" of cancer drugs, but there is no data on what oncologists and patients perceive as meaningful benefit or justified prices.

We interviewed Indian oncologists and established that a 4.5-month improvement in PFS or OS was expected as a minimum from cancer drugs. The justified price for this improvement was 120 USD a month for PFS drugs and 360 USD a month for OS drugs.

We thus established the first benchmark for what constitutes meaningful benefit and justified drug prices.

Next step would be to interview oncologists in other LMICs as well as HICs to set these benchmarks, as well as interview patients to gain perspectives from patients' side on what constitutes meaningful gains and prices for cancer drugs. We are planning such studies and looking for funders :)
Stay tuned!

Huge kudos to @HealthCommunic2 who led this project from inception to finish. Proud of all coauthors and collaborators @MONBAUL @mindfullstate @sanjitgrwl and @SirohiBhawna.

Thanks to @ESMO_Open @curijoey for publishing this #openaccess.
#globaloncology
#globaloncology #cancerpolicy